Biotherapeutics

Talecris Biotherapeutics Receives Orphan Drug Designation for Aerosolized Form of Alpha1-Antitrypsin From the European Commission 2008-07-24 17:49:04 - www.talecris.com - Talecris Biotherapeutics, Inc.  

Northwest Biotherapeutics, Inc. , , today announced that Dr. Alton L. Boynton, its President and Chief Executive Officer, will deliver a presentation updating the Company's progress in the development of ...  

GTC Biotherapeutics Inc. reports it has received yet another notice from the Nasdaq Global Market that the biotech firm's stock doesn't comply with listing requirements.  

The Company ' s common stock is subject to delisting unless the Company requests a hearing before a NASDAQ Listing Qualifications Panel .  

GTC Biotherapeutics, Inc. announced today that Geoffrey Cox, Ph.D., GTC ' s Chairman and CEO, is scheduled to present on Wednesday, July 9, 2008 at 3:30 p.m. during the Collins Stewart Fourth Annual Growth ...  

Main Category: Clinical Trials / Drug Trials Also Included In: Regulatory Affairs / Drug Approvals Article Date: 14 Jul 2008 Oxygen Biotherapeutics, Inc.  

GTC Biotherapeutics, Inc. has received a Staff Deficiency Letter from The Nasdaq Stock Market notifying GTC that for the last 10 consecutive trading days the aggregate market value of GTCB common stock has ...  

Effective today, Oxygen Biotherapeutics, Inc. is the new name for the company previously known as Synthetic Blood International, Inc.  

Protalix BioTherapeutics, Inc. , today announced that on June 27 th , 2008, the Company was added to the Russell Microcap Index as part of the Russell Investment Group ' s reconstitution of its family of U.S. ...